| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.
|
Cancer Cell
|
2009
|
4.48
|
|
2
|
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.
|
Blood
|
2010
|
2.25
|
|
3
|
MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer.
|
PLoS One
|
2013
|
1.82
|
|
4
|
Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults.
|
Atherosclerosis
|
2010
|
1.71
|
|
5
|
TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF.
|
Blood
|
2004
|
1.66
|
|
6
|
TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation.
|
Clin Sci (Lond)
|
2012
|
1.49
|
|
7
|
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets.
|
Proc Natl Acad Sci U S A
|
2002
|
1.39
|
|
8
|
The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology.
|
Cytokine Growth Factor Rev
|
2006
|
1.26
|
|
9
|
Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity.
|
Blood
|
2004
|
1.17
|
|
10
|
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells.
|
Circ Res
|
2003
|
1.17
|
|
11
|
miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.
|
Clin Cancer Res
|
2011
|
1.11
|
|
12
|
Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
|
Clin Cancer Res
|
2010
|
1.04
|
|
13
|
Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes.
|
Am J Pathol
|
2005
|
1.04
|
|
14
|
Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes.
|
Diabetes
|
2010
|
1.03
|
|
15
|
Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo.
|
Blood
|
2007
|
1.03
|
|
16
|
NK-active cytokines IL-2, IL-12, and IL-15 selectively modulate specific protein kinase C (PKC) isoforms in primary human NK cells.
|
Anat Rec
|
2002
|
0.98
|
|
17
|
Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype.
|
PLoS One
|
2012
|
0.97
|
|
18
|
Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation.
|
J Cell Physiol
|
2006
|
0.97
|
|
19
|
The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
|
Haematologica
|
2012
|
0.96
|
|
20
|
Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells.
|
J Neurochem
|
2003
|
0.96
|
|
21
|
The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement.
|
Acta Diabetol
|
2013
|
0.94
|
|
22
|
TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors.
|
J Cell Physiol
|
2008
|
0.90
|
|
23
|
Cell-based therapies for diabetic complications.
|
Exp Diabetes Res
|
2011
|
0.90
|
|
24
|
In vitro characterization of circulating endothelial progenitor cells isolated from patients with acute coronary syndrome.
|
PLoS One
|
2013
|
0.89
|
|
25
|
Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets.
|
Mol Cell Endocrinol
|
2010
|
0.87
|
|
26
|
Endothelial PDGF-BB produced ex vivo correlates with relevant hemodynamic parameters in patients affected by chronic venous disease.
|
Cytokine
|
2013
|
0.87
|
|
27
|
MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3.
|
Br J Haematol
|
2010
|
0.86
|
|
28
|
MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway.
|
J Bone Miner Res
|
2007
|
0.86
|
|
29
|
Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase.
|
Int J Oncol
|
2004
|
0.84
|
|
30
|
TRAIL and osteoprotegerin: a role in endothelial physiopathology?
|
Front Biosci
|
2008
|
0.84
|
|
31
|
TRAIL shows potential cardioprotective activity.
|
Invest New Drugs
|
2011
|
0.84
|
|
32
|
TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases.
|
Curr Drug Targets
|
2012
|
0.84
|
|
33
|
Mechanisms of remodelling: a question of life (stem cell production) and death (myocyte apoptosis).
|
Circ J
|
2009
|
0.83
|
|
34
|
Association of soluble Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL) with central adiposity and low-density lipoprotein cholesterol.
|
PLoS One
|
2013
|
0.83
|
|
35
|
Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop.
|
Atherosclerosis
|
2011
|
0.82
|
|
36
|
State of art and recent developments of anti-cancer strategies based on TRAIL.
|
Recent Pat Anticancer Drug Discov
|
2012
|
0.82
|
|
37
|
The puzzling role of TRAIL in endothelial cell biology.
|
Arterioscler Thromb Vasc Biol
|
2008
|
0.81
|
|
38
|
MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib.
|
Br J Haematol
|
2012
|
0.81
|
|
39
|
Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
|
Clin Cancer Res
|
2011
|
0.81
|
|
40
|
Proper design of silica nanoparticles combines high brightness, lack of cytotoxicity and efficient cell endocytosis.
|
Nanoscale
|
2013
|
0.81
|
|
41
|
Correction: MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer.
|
PLoS One
|
2015
|
0.80
|
|
42
|
Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells.
|
J Cell Physiol
|
2011
|
0.80
|
|
43
|
Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development.
|
J Cell Physiol
|
2005
|
0.80
|
|
44
|
TRAIL administration down-modulated the acute systemic inflammatory response induced in a mouse model by muramyldipeptide or lipopolysaccharide.
|
Cytokine
|
2012
|
0.80
|
|
45
|
Nanoparticles engineered with rituximab and loaded with Nutlin-3 show promising therapeutic activity in B-leukemic xenografts.
|
Clin Cancer Res
|
2013
|
0.80
|
|
46
|
Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR8 trophoblastic cells.
|
Hum Reprod
|
2012
|
0.80
|
|
47
|
TNF-alpha modulates the migratory response of mesenchymal stem cells to TRAIL.
|
Cell Mol Life Sci
|
2010
|
0.80
|
|
48
|
The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis.
|
Rheumatology (Oxford)
|
2009
|
0.80
|
|
49
|
The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker?
|
Rheumatology (Oxford)
|
2010
|
0.79
|
|
50
|
GM-CSF exhibits anti-inflammatory activity on endothelial cells derived from chronic venous disease patients.
|
Mediators Inflamm
|
2013
|
0.79
|
|
51
|
The energy balance positively regulates the levels of circulating TNF-related apoptosis inducing ligand in humans.
|
Clin Nutr
|
2012
|
0.79
|
|
52
|
Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells.
|
Invest New Drugs
|
2010
|
0.79
|
|
53
|
Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL.
|
Invest New Drugs
|
2010
|
0.79
|
|
54
|
Receptor activator of nuclear factor kappa B ligand (RANKL) modulates the expression of genes involved in apoptosis and cell cycle in human osteoclasts.
|
Anat Rec (Hoboken)
|
2007
|
0.78
|
|
55
|
Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis.
|
Exp Hematol
|
2004
|
0.78
|
|
56
|
Circulating levels of frizzled-related protein (FRZB) are increased in patients with early rheumatoid arthritis and decrease in response to disease-modifying antirheumatic drugs.
|
Ann Rheum Dis
|
2010
|
0.77
|
|
57
|
Inverse correlation between circulating levels of TNF-related apoptosis-inducing ligand and 17β-estradiol.
|
J Clin Endocrinol Metab
|
2014
|
0.77
|
|
58
|
Human herpesvirus 7 infection impairs the survival/differentiation of megakaryocytic cells.
|
Haematologica
|
2002
|
0.77
|
|
59
|
Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity.
|
Br J Haematol
|
2009
|
0.77
|
|
60
|
The circulating levels of TRAIL are extremely low after delivery but rapidly recover in both mothers and newborns.
|
Cytokine
|
2013
|
0.77
|
|
61
|
Potential role of TRAIL in the management of autoimmune diabetes mellitus.
|
Curr Pharm Des
|
2012
|
0.76
|
|
62
|
Letter by Secchiero and Zauli regarding article, "Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice".
|
Circulation
|
2008
|
0.76
|
|
63
|
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
|
J Hematol Oncol
|
2013
|
0.76
|
|
64
|
Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin.
|
J Cell Mol Med
|
2008
|
0.76
|
|
65
|
Patients affected by metabolic syndrome show decreased levels of circulating platelet derived growth factor (PDGF)-BB.
|
Clin Nutr
|
2012
|
0.76
|
|
66
|
Molecular targets for selective killing of TRAIL-resistant leukemic cells.
|
Expert Opin Ther Targets
|
2011
|
0.76
|
|
67
|
Circulating TRAIL shows a significant post-partum decline associated to stressful conditions.
|
PLoS One
|
2011
|
0.76
|
|
68
|
Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells.
|
Invest New Drugs
|
2011
|
0.76
|
|
69
|
Release of a specific set of proinflammatory adipokines by differentiating 3T3-L1 cells.
|
Nutrition
|
2013
|
0.76
|
|
70
|
TRAIL, a new weapon against neointimal hyperplasia.
|
Cardiology
|
2012
|
0.76
|
|
71
|
Levels of TNF-related apoptosis-inducing ligand (TRAIL) show a long-term stability in the breast milk of mothers of preterm infants.
|
J Hum Lact
|
2013
|
0.76
|
|
72
|
JCV+ Patients with Inflammatory bowel disease show elevated plasma levels of MIG and SCF.
|
Inflamm Bowel Dis
|
2012
|
0.76
|
|
73
|
Potential involvement of TRAIL in Treg cell-mediated osteoclast suppression: comment on the article by Zaiss et al.
|
Arthritis Rheum
|
2008
|
0.75
|
|
74
|
Reduced expression of cell cycle-associated genes in B lymphocytes purified from the peripheral blood of early-stage B chronic lymphocytic leukaemia patients.
|
Br J Haematol
|
2009
|
0.75
|
|
75
|
In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody.
|
Invest New Drugs
|
2010
|
0.75
|
|
76
|
TRAIL activates a caspase 9/7-dependent pathway in caspase 8/10-defective SK-N-SH neuroblastoma cells with two functional end points: induction of apoptosis and PGE2 release.
|
Neoplasia
|
2003
|
0.75
|
|
77
|
Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1.
|
Invest New Drugs
|
2012
|
0.75
|
|
78
|
TRAIL, caspases and maturation of normal and leukemic myeloid precursors.
|
Leuk Lymphoma
|
2006
|
0.75
|
|
79
|
The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL.
|
Invest New Drugs
|
2010
|
0.75
|
|
80
|
Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3.
|
Mol Carcinog
|
2012
|
0.75
|
|
81
|
Simultaneous determination of multiple cytokines reveals a pro-inflammatory and pro-angiogenic signature after major cardiothoracic surgery: potential role of C-reactive protein.
|
Cytokine
|
2012
|
0.75
|
|
82
|
Unsung hero Robert C. Gallo.
|
Science
|
2009
|
0.75
|
|
83
|
Serum Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Levels in Older Subjects with Dementia and Mild Cognitive Impairment.
|
Dement Geriatr Cogn Disord
|
2016
|
0.75
|
|
84
|
IFN-alpha2b increases interleukin-10 expression in primary activated human CD8+ T cells.
|
J Interferon Cytokine Res
|
2002
|
0.75
|
|
85
|
Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
|
J Cell Physiol
|
2010
|
0.75
|
|
86
|
MicroRNAs as new players in the genomic galaxy and disease puzzles.
|
Clin Transl Sci
|
2008
|
0.75
|
|
87
|
Merkel-cell polyomavirus (MCPyV) is rarely associated to B-chronic lymphocytic leukemia (1 out of 50) samples and occurs late in the natural history of the disease.
|
J Clin Virol
|
2012
|
0.75
|
|
88
|
Human colostrum and breast milk contain high levels of TNF-related apoptosis-inducing ligand (TRAIL).
|
J Hum Lact
|
2012
|
0.75
|